Feb 9th: The Maze of PARP Inhibitors in Ovarian Cancer - Cancer Network Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, February 09, 2012

Feb 9th: The Maze of PARP Inhibitors in Ovarian Cancer - Cancer Network



Blogger's Note:  full access, free subscription

Conclusion

"While consideration of chemoprevention with PARP inhibitors is on the horizon, many knowledge gaps exist regarding these agents. Although the trials in EOC provided some answers regarding the activity of PARP inhibitors, they raised many other questions. These questions may actually complicate the picture as newer agents in this drug class make their way to the clinical arena. A collaborative approach among the researchers is needed to systematically answer these questions so we are better equipped to provide effective treatment to the BRCA-deficient patients. It is noteworthy that The Cancer Genome Atlas Group analysis did reveal other commonly deregulated pathways in this disease—such as RB, RAS/PI3K, FOXM1, and NOTCH—that might provide future opportunities for therapeutic targeting while the story of the PARP inhibitors continues to unfold."


 

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.